BioCryst Pharma (BCRX) Tops Q1 EPS by 4c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.22 +0.88%
Revenue Growth %: +13.7%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +13.7%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $4.3 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
